Risk Stratification Models for Precursor Diseases in Multiple Myeloma
Betsy O'Donnell, MD
From MGUS to Multiple Myeloma: Understanding the Progression of Precursor Diseases
Diversity in HER2 Expression Among Gynecologic Cancers
Ritu Salani, MD
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Expanding Horizons: HER2 Targeting in Metastatic Solid Tumors
Shubham Pant, MD, MBBS
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
Significance of HER2 Expression in Solid Tumors
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
Justin Gainor, MD
Jacob Sands, MD
Uncovering New Biomarkers for RCC: A Review of Emerging Techniques
Jody Takemoto, PhD, MEd
David Braun
The Potential Impact of RCC Molecular Subtypes on Treatment Outcomes
David Braun, MD, PhD
Enhancing HCC Outcomes Through Multidisciplinary Care
Charles Turck, PharmD, BCPS, BCCCP
Hannah Lee, MD
Optimizing HCC Screening: Strategies to Overcome Common Barriers
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.